Lilly's BLAZE-1 trial showed that large mAB doses are effective, but the FDA believes lower doses will have a similar clinical effect. • Source: Shutterstock
Learn what's happening at the US FDA. On the go.
Derrick Gingery and the team bring you a weekly "Drug Fix".
